WEDNESDAY, Aug. 28, 2024 -- Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points...
Vous n'êtes pas connecté
TUESDAY, July 9, 2024 -- Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published...
WEDNESDAY, Aug. 28, 2024 -- Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points...
TUESDAY, Sept. 3, 2024 -- Treatment with semaglutide does not increase the risk for developing symptoms of depression or suicidal ideation/behavior...
According to research presented today at ESC Congress 2024, patients with stable coronary artery disease who quit smoking at any timepoint after their...
Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an...
TUESDAY, Sept. 10, 2024 -- For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations,...
TUESDAY, Sept. 3, 2024 -- In patients with newly diagnosed type 2 diabetes, baseline interleukin-6 (IL-6) levels may enhance prediction of new-onset...
MONDAY, Sept. 9, 2024 -- Cancer diagnosis is associated with an increased risk for psychological illness and cardiovascular disease among...
THURSDAY, Aug. 29, 2024 -- Greater television viewing in young adulthood is associated with incident cardiovascular disease (CVD) later in life,...
THURSDAY, Sept. 5, 2024 -- Weekly mobile phone usage is positively associated with incident cardiovascular disease (CVD) risk over 12 years, according...
The European Society of Cardiology (ESC) has released a Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at the ESC...